Literature DB >> 19960981

[Effect of tongxinluo on mini-swine cytokines and myocardial no-reflow in early reperfusion of acute myocardial infarction].

Hai-Tao Zhang1, Yue-Jin Yang, Yu-Tong Cheng.   

Abstract

OBJECTIVE: To assess the effect of Tongxinluo on cytokines and myocardial no-reflow in early reperfusion of acute myocardial infarction (AMI).
METHODS: Forty mini-swine were divided into five groups randomly, sham group, control group, low dose (0.1 g/kg), medium dose (0.2 g/kg) and high dose (0. 4 g/kg) group of Tongxinluo (which were administered 2 h before reperfusion), eight swine in each group. Animals except those in the sham group were subjected to 1.5 h of coronary occlusion followed by 3 h of reperfusion. Serum contents of P-selectin, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), interleukin 6 (IL-6) and interleukin 10 (IL-10), as well as myocardial contrast echocardiography (MCE) were evaluated at baseline, and after 1.5 h of AMI and 3 h of reperfusion.
RESULTS: (1) Compared with that of the control group, high dose of Tongxinluo could reduce serum contents of P-selectin and ICAM-1 at 1.5 h of AMI (all P<0.05), and P-selectin, ICAM-1, VCAM-1, and IL-6 at 3 h of reperfusion significantly (all P< 0.05), accompanied by significantly elevated IL-10 (P<0.05). (2) Compared with that of control group, high dose of Tongxinluo could reduce no-reflow area at 3 h of reperfusion significantly [(6.59 +/- 1.73) cm2 vs (4.68 +/- 1.53) cm2, P<0.05].
CONCLUSION: High dose of Tongxinluo could effectively reduce serum contents of adhesion and pro-inflammatory cytokines, regulate anti-inflammatory factor levels, and attenuate no-reflow area in the early reperfusion of AMI. It thus provided experimental basis for its clinical application.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19960981

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

1.  Potential Effectiveness of Chinese Patent Medicine Tongxinluo Capsule for Secondary Prevention After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Min Li; Chengyu Li; Shiqi Chen; Yang Sun; Jiayuan Hu; Chen Zhao; Ruijin Qiu; Xiaoyu Zhang; Qin Zhang; Guihua Tian; Hongcai Shang
Journal:  Front Pharmacol       Date:  2018-08-03       Impact factor: 5.810

2.  China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial.

Authors:  Yi Xu; Xiangdong Li; Haitao Zhang; Yuan Wu; Jun Zhang; Jia Li; Kefei Dou; Hongbing Yan; Shijie You; Yanmin Yang; Yan Liang; Lianjun Xu; Xiaojin Gao; Chen Liu; Qiuting Dong; Wenjia Zhang; Guangyuan Song; Tao Zhang; Lin Jiang; Guihao Chen; Ruijie Tang; Chen Jin; Jingang Yang; Chen Yao; Ying Xian; Eric D Peterson; Runlin Gao; Yuejin Yang
Journal:  Am Heart J       Date:  2020-06-20       Impact factor: 4.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.